Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’

Moderna will present detailed Phase 3 results for its personalized cancer therapy, Intismeran, at the ESMO Congress on October 24, 2026. This therapy, developed with Merck, previously showed significant improvements in melanoma recurrence-free and distant metastasis-free survival when combined with Keytruda. Retail investors are increasingly optimistic about Moderna's stock, with some believing this cancer therapy could be revolutionary.